Liver/Biliary Disorders News

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

BOSTON — Response to treatment for acute kidney injury correlated with improved 90-day survival and shorter lengths of hospital stay among patients with cirrhosis waitlisted for liver transplant, according to data at The Liver Meeting.

BOSTON — Transarterial chemoembolization with vitamin K dosing improved anticancer outcomes of objective response and progression-free survival in patients with hepatocellular carcinoma, according to a researcher at The Liver Meeting.

BOSTON — Resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis was linked to long-term survival after bariatric surgery, similar to that of patients without baseline MASH, according to a presenter.

BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.

SAN DIEGO — Patients with rheumatoid arthritis who receive hydroxychloroquine demonstrate a lower risk for nonalcoholic fatty liver disease, according to data presented at ACR Convergence 2023.

BOSTON — Metabolic dysfunction-associated steatohepatitis is currently the most common indication for liver transplantation in patients with hepatocellular carcinoma, increasing from 10% in 2013 to 31% in 2022, according to a presenter.

BOSTON — Researchers reported similar patient and allograft survival 1 year after liver transplantation between COVID-19 positive and negative donors, showing potential for expanding organ access, according to data at The Liver Meeting.